Aligos Therapeutics (ALGS) vs Actinium Pharmaceuticals (Delaware) (ATNM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Actinium Pharmaceuticals (Delaware) (ATNM) has outperformed Aligos Therapeutics (ALGS) over the past year, losing 29.9% versus a loss of 46.5%. Over five years, ATNM leads with a -86.7% price change compared with -98.7% for ALGS. Actinium Pharmaceuticals (Delaware) is the larger company by market cap ($34.0 million vs $33.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALGS | ATNM |
|---|---|---|
| Share price | $5.31 | $1.08 |
| Market cap | $33.16M | $33.96M |
| 1-day change | -0.19% | +0.93% |
| YTD return | -43.03% | -20.59% |
| 1-year return | -46.53% | -29.87% |
| 5-year return | -98.66% | -86.69% |
| P/E ratio (TTM) | — | 3.00 |
| EPS (TTM) | $-7.33 | $0.36 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $13.69 | $1.74 |
| 52-week low | $3.98 | $0.735 |
| Distance from 52-week high | -61.21% | -37.93% |
| Analyst consensus | none | none |
| Avg. price target upside | +886.44% | +233.33% |
| Average volume | 88.98K | 138.94K |
| Shares outstanding | 5.44M | 31.44M |
| Employees | 82 | 27 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ATNM has outperformed ALGS by 16.7 percentage points over the past year.
About Aligos Therapeutics
ALGS stock →Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis and obesity.
Healthcare · Biotechnology · 82 employees
About Actinium Pharmaceuticals (Delaware)
ATNM stock →Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies.
Healthcare · Biotechnology · 27 employees
ALGS vs ATNM FAQ
Which is bigger, Aligos Therapeutics or Actinium Pharmaceuticals (Delaware)?
Actinium Pharmaceuticals (Delaware) (ATNM) is larger, with a market capitalization of $33.96M compared with $33.16M for Aligos Therapeutics (ALGS).
Which stock has performed better over the past year, ALGS or ATNM?
ATNM returned -29.87% over the past 12 months, compared with -46.53% for ALGS (price return, excluding dividends). Past performance does not predict future results.
Are Aligos Therapeutics and Actinium Pharmaceuticals (Delaware) in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.